Pictor
Overview
Pictor is pleased to announce a new NZD13.4 million B series round (organically this is round H). This investment round is led by former Morrison & Co CEO Marko Bogoievski and specialist growth investor K One W One Ltd (K1W1) and will be invested in accelerating the Product Development for 4 upcoming product launches. Round H will enable Pictor to continue to accelerate Product Development and Commercial efforts to successfully launch 4 more diagnostic products in the next 12 months.
We have NZD9.3M committed, and we are looking for a further NZD4.1M to bridge the achievement of near-term commercial milestones which will enable the business to hit revenue milestones of NZD8.2m in FY25, NZD27.4m in FY26 and NZD38M in FY27, and achieve positive EBITDA by November 2024.
Investment Highlights
- Pictor has developed novel diagnostic tests that allow up to 10 diseases or biomarkers to be detected from one sample.
- This high-efficacy diagnostic multiplexed platform is capable of identifying infectious and complex diseases for human and animal health.
- After 5+ years of Product Development, Pictor has developed a strong commercial pipeline of products for their patented multiplexed diagnostics platform.
- Pictor is close to achieving several significant commercial milestones in several human and animal health products within the next 6-12 months.
- Upon achieving these milestones, Pictor will accelerate the commercialisation of further animal and human health products in the pipeline and bring forward product development on future products and applications.
- Pictor is seeking investment to bridge these near-term commercial milestones. Investment prior to key trial results and external validation represents an opportunity to realise a significant valuation uplift upon achievement of the commercial milestones.
We invite any interested parties to contact us for further information or updates.
Problem and Solution
Ut dignissim eget felis non ultrices. Vivamus fermentum erat at velit varius molestie.
Duis vitae mi neque. Donec tincidunt, dolor luctus lobortis ultrices, turpis eros cursus turpis, maximus tempor lectus lectus vel diam.
Proin neque lacus, semper vel ex at, eleifend rhoncus est.
Cras non nisi urna. Sed feugiat dignissim erat, eget convallis nisl blandit a.
Nullam fringilla diam eget dui placerat fermentum. Maecenas malesuada viverra leo eu bibendum. Nam vulputate enim velit, eu pretium justo tristique ac.
Nam vitae varius augue. Nam pharetra facilisis elementum. Sed nisl risus, vestibulum ut velit at, dapibus sagittis arcu.
Nullam sed dolor suscipit, efficitur enim quis, vestibulum sapien. Nunc convallis mauris nec nibh mollis, eget aliquet odio tincidunt.
Phasellus faucibus sem mauris, sed iaculis nisl egestas sed.
Sed sit amet gravida elit, sagittis sollicitudin nulla. Vivamus auctor arcu eu scelerisque convallis. Phasellus scelerisque ultrices tincidunt. Curabitur odio libero, faucibus et felis nec, pulvinar facilisis urna. Interdum et malesuada fames ac ante ipsum primis in faucibus. Maecenas ultrices in velit at ultrices.
Pellentesque tempor a risus in elementum. Proin malesuada mauris et mauris bibendum laoreet. Vivamus maximus nulla volutpat, ornare lorem a, vulputate enim.
In dui nisl, vestibulum eu finibus pretium, eleifend et eros. Vivamus in venenatis risus, ut dictum velit. Praesent rh
Market Opportunity
Cras eleifend purus vitae mattis imperdiet.
Integer fringilla mi ut sem tincidunt, in sagittis odio mollis. Suspendisse a diam lectus. Cras at suscipit risus.
Fusce gravida, ante quis mattis ultricies, lorem neque suscipit ex, semper tincidunt dui mi sit amet elit.
Fusce scelerisque massa sit amet turpis rutrum semper.
Donec ac orci aliquet, tincidunt ligula eu, finibus libero. Pellentesque pharetra consequat congue. Pellentesque quis dolor augue.
Proin non ipsum vel risus rutrum porta. Vivamus sem enim, interdum pretium metus eu, ornare posuere nisl. Duis venenatis accumsan enim, quis blandit lacus posuere at. Sed tincidunt congue blandit. Maecenas interdum quam in mauris condimentum luctus. Donec fermentum egestas risus vel cursus. Ut metus justo, rutrum vel sem ut, consequat laoreet ante. Nunc tincidunt viverra metus, tincidunt viverra elit iaculis sit amet. Integer ullamcorper hendrerit eleifend. Curabitur massa nisi, tempus eget fermentum quis, volutpat non sem. Integer id sagittis dolor. Donec nunc erat, maximus sed magna
Competitive Advantage
Cras eleifend purus vitae mattis imperdiet.
Integer fringilla mi ut sem tincidunt, in sagittis odio mollis. Suspendisse a diam lectus. Cras at suscipit risus.
Fusce gravida, ante quis mattis ultricies, lorem neque suscipit ex, semper tincidunt dui mi sit amet elit.
Fusce scelerisque massa sit amet turpis rutrum semper.
Donec ac orci aliquet, tincidunt ligula eu, finibus libero. Pellentesque pharetra consequat congue. Pellentesque quis dolor augue.
Proin non ipsum vel risus rutrum porta. Vivamus sem enim, interdum pretium metus eu, ornare posuere nisl. Duis venenatis accumsan enim, quis blandit lacus posuere at. Sed tincidunt congue blandit. Maecenas interdum quam in mauris condimentum luctus. Donec fermentum egestas risus vel cursus. Ut metus justo, rutrum vel sem ut, consequat laoreet ante. Nunc tincidunt viverra metus, tincidunt viverra elit iaculis sit amet. Integer ullamcorper hendrerit eleifend. Curabitur massa nisi, tempus eget fermentum quis, volutpat non sem. Integer id sagittis dolor. Donec nunc erat, maximus sed magna id, faucibus ultricies velit. Nunc lobortis eget urna at semper.
Donec sollicitudin, tortor ac interdum tempus, mi odio fringilla lacus, sit amet hendrerit mi purus vel nisi. Phasellus nulla ligula, congue quis ullamcorper eget, egestas id leo. Sed et rhoncus libero. Mauris tincidunt ultricies justo ut tincidunt. Nam rhoncus est non erat auctor mattis. Sed quis consectetur ma
Highlights & Milestones
Cras eleifend purus vitae mattis imperdiet.
Integer fringilla mi ut sem tincidunt, in sagittis odio mollis. Suspendisse a diam lectus. Cras at suscipit risus.
Fusce gravida, ante quis mattis ultricies, lorem neque suscipit ex, semper tincidunt dui mi sit amet elit.
Fusce scelerisque massa sit amet turpis rutrum semper.
Donec ac orci aliquet, tincidunt ligula eu, finibus libero. Pellentesque pharetra consequat congue. Pellentesque quis dolor augue.
Proin non ipsum vel risus rutrum porta. Vivamus sem enim, interdum pretium metus eu, ornare posuere nisl. Duis venenatis accumsan enim, quis blandit lacus posuere at. Sed tincidunt congue blandit. Maecenas interdum quam in mauris condimentum luctus. Donec fermentum egestas risus vel cursus. Ut metus justo, rutrum vel sem ut, consequat laoreet ante. Nunc tincidunt viverra metus, tincidunt viverra elit iaculis sit amet. Integer ullamcorper hendrerit eleifend. Curabitur massa nisi, tempus eget fermentum quis, volutpat non sem. Integer id sagittis dolor. Donec nunc erat, maximus sed magna id, faucibus ultricies velit. Nunc lobortis eget urna at semper.
Donec sollicitudin, tortor ac interdum tempus, mi odio fringilla lacus, sit amet hendrerit mi purus vel nisi. Phasellus nulla ligula, congue quis ullamcorper eget, egestas id leo. Sed et rhoncus libero. Mauris tincidunt ultricies justo ut tincidunt. Nam rhoncus est non erat auctor mattis. Sed quis consectetur ma
See more exiting opportunities on CapitalHQ
Pictor
Powering diagnostics with protein signatures. Pictor is transforming health with its patented platform providing accessible, affordable, and scalable diagnostic solutions across the human and animal health verticals. PictArray can detect up to 10 diseases or biomarkers from one small serum, milk,...
ProxyTwin
ProxyTwin™ amplifies expertise. ProxyTwin is a digital twin that works for experts so they can help more people. We create advanced digital replicas of real individuals, enabling them to virtually attend meetings, deliver messages, and hold thousands of interactions simultaneously. Recently...
HorizonTwo Capital Partners
HorizonTwo Capital Partners is a private equity firm that specialises in advanced manufacturing companies.
The Insides Company
First-in-class medtech for intestinal failure. Seeking remaining $1M of a $5M round, on a AUD$17.2M pre-money valuation.
DCARB
We are aiming to raise $CAD5M to fund the ongoing commercialisation of the D100 unit, including working capital to fund the expected growth in sales, and a field trial of the DArc unit. This follows a successful Series B round completed in mid-2023.
Grabba Technologies Pty Ltd
Advanced manufacturer of biometric identity authorisation products and electronics supplier to defence industry. We invite expressions of interest for up to $10.0M in growth capital.
Backed By Leading Investment Groups and Family Offices
